Sellas Life Sciences has dosed the first paediatric subject with AML in its Phase II trial of SLS009 (tambiciclib).

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

According to the British Academy of Audiology, hearing loss (HL) is the second most common disability in the UK, affecting ...

Nuance Pharma’s Ohtuvayre has met the primary endpoint in a Phase III chronic obstructive pulmonary disease (COPD) study in ...

Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with daraxonrasib (RMC-6236) for NSCLC.

ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...

Roche has reported overall survival outcomes from a Phase III trial of Perjeta with Herceptin and chemotherapy in early-stage ...

People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...